Henning Steinhagen

Henning Steinhagen, PhD, MBA, serves as the CEO and Co-founder of Lario Therapeutics, which focuses on developing precision medicines for severe neurological disorders since November 2021. In addition, Henning is also the CEO and Co-founder of Epidarex Exeed, the therapeutic discovery engine of Epidarex Capital, and a Venture Partner at Epidarex Capital, investing in early-stage life science and health technology companies. Henning holds director positions at Libra Therapeutics and Theolytics, contributing to the development of therapeutics for neurodegenerative diseases and oncolytic viral therapies, respectively. Through various consulting roles, Henning has supported numerous projects in Newco formation and strategy development. Other past leadership roles include positions at Caldan Therapeutics, Aptuit, Grünenthal Pharma, and Sanofi-Aventis, further underscoring extensive experience in drug discovery and development. Educational qualifications include an Executive MBA from IMD, a Postdoc from Harvard University, and a combined Master and PhD in Chemistry from Heidelberg University.